SanaHeal is developing ways to attach materials to wet tissue, but a successful laboratory bond is only one part of making a surgical product. The MIT spinout’s story spans historical tape research, a separately funded paste project and proposed human studies. Those stages should not be collapsed into proof that one approved product can replace stitches. MIT account
The 20 October account describes a company working to translate adhesive research into products through device-industry partnerships. It reports plans for human trials in 2027. A future trial date is a development plan, not a clinical result.
The problem begins at the wet interface
The original 2019 Nature paper describes a dry, double-sided tape designed to take up water from the contact surface and then form stabilising bonds with tissue. Removing water at the interface addresses a problem that ordinary dry-surface sticking does not capture. Author-hosted original paper
The work included in vitro mouse tissue, in vivo rat experiments and ex vivo porcine tissue. These are different experimental settings; none is a clinical trial in people. The paper provides a mechanism and preclinical demonstrations, not a measured rate of benefit from today’s company products.
The distinction matters because a material can adhere in an experiment without answering every question about a procedure. How it is applied, how it behaves over time and what happens in a particular patient population remain separate evidential tasks. The laboratory result creates questions for translation rather than answering them all.
Tape and paste are different development paths
A federal phase II award record identifies a SanaHeal project on hemostatic bioadhesive paste. The 2024 NIH-funded project describes optimisation and preclinical validation towards later clinical and regulatory steps. It is a funding record containing proposed work, not a report that those steps have been completed. SBIR award record
This adds useful context beyond the tape illustration: a company can develop more than one material format for different tasks. It would be misleading to take evidence for the earlier tape and apply it directly to the paste, or to treat an award’s intended outcome as an achieved product claim.
The two formats also show why “surgical glue” can be too broad a label. Sticking a surface, sealing a site and controlling bleeding are distinct proposed functions. A shared adhesive mechanism does not make their evidence or intended uses interchangeable.
Development plans do not establish clinical availability
SanaHeal’s current website labels its materials for research use and not human use. That statement should not be stretched into a complete regulatory history for every possible product, but it gives no basis for presenting the site’s materials as available clinical treatments. Company website
MIT’s founder account helps explain the intended translation route. The earlier research and federal award describe parts of the technical development. They do not collectively establish a named product’s authorised indication, superior healing, lower complication rates or cost savings. MIT account
The next meaningful evidence would identify the particular material, intended use and study population, then report what happened. Until then, SanaHeal is a useful case study in the distance between solving a materials problem and establishing a clinical product.